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DefenseRetroviruses must integrate their cDNA to a host chromosome, but a signiﬁcant fraction of retroviral cDNA is
degraded before integration. XPB and XPD are part of the TFIIH complex which mediates basal transcription
and DNA nucleotide excision repair. Retroviral infection increases when XPB or XPD are mutant. Here we
show that inhibition of mRNA or protein synthesis does not affect HIV cDNA accumulation suggesting that
TFIIH transcription activity is not required for degradation. Other host factors implicated in the stability of
cDNA are not components of the XPB and XPD degradation pathway. Although an increase of retroviral cDNA
in XPB or XPDmutant cells correlates with an increase of integrated provirus, the integration efﬁciency of pre-
integration complexes is unaffected. Finally, HIV and MMLV cDNA degradation appears to coincide with
nuclear import. These results suggest that TFIIH mediated cDNA degradation is a nuclear host defense against
retroviral infection., OH 43210, USA. Fax: +1 614
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All retroviruses reverse transcribe a genomic RNA to a linear cDNA
molecule (Cofﬁn et al., 1997). The cDNA is part of a pre-integration
complex (PIC) which includes at least the viral proteins reverse
transcriptase, matrix, and integrase (Miller et al., 1997). The retroviral
PIC integrates the cDNA into a host chromosome to continue the viral
life cycle. Retroviruses, including Molony murine leukemia virus
(MMLV), require cellular division and breakdown of the nuclear
envelope for the PIC to enter the nucleus. Lentiviruses, such as HIV, do
not require cellular division and can traverse an intact nuclear
envelope. Previous studies have shown that most of the cDNA that
completes reverse transcription will be degraded before integration
(Barbosa et al., 1994; Brussel and Sonigo, 2003; Butler et al., 2002; Van
Maele et al., 2003; Vandegraaff et al., 2001).
Several host proteins have been shown to inhibit viral replication
before integration (Goff, 2004). Most notably, APOBEC3G deaminates
cytosines during reverse transcription (Harris et al., 2003; Mangeat
et al., 2003). APOBEC3G has also been shown to reduce the
accumulation of cDNA, but this ﬁnding is controversial (Bishopet al., 2006). The proteasome has been shown to play a role in cDNA
stability (Butler et al., 2002; Schwartz et al., 1998). In the presence of
proteasome inhibitors more retroviral cDNA accumulates. Similarly,
mutations of the host XPB (ERCC3) and XPD (ERCC2) proteins
correlate with an increase of retroviral cDNA (Yoder et al., 2006). The
kinetics of cDNA accumulation is affected by the rate of reverse
transcriptase synthesis and the rate of degradation. Degradation of
cDNA may be analyzed by abrogating synthesis with the non-
nucleoside reverse transcriptase inhibitor efavirenz. Treatment of
XPB or XPDmutant cells with efavirenz following infection resulted in
a signiﬁcantly slower decrease of HIV cDNA compared to wild type
cells, suggesting that these proteins participate in a cDNA degradation
pathway (Yoder et al., 2006).
XPB and XPD are part of TFIIH, a ten-subunit complex that
participates in both basal transcription and DNA nucleotide excision
repair (NER; Giglia-Mari et al., 2004; Ranish et al., 2004). During
transcription TFIIH unwinds promoter DNA allowing RNA polymerase
access to the DNA template. TFIIH participates in NER by unwinding
the DNA helix at the site of DNA damage. XPB and XPD are ATPase
helicases with opposing polarity. XPB 3′→5′ helicase activity is
required for transcription while XPD 5′→3′ helicase activity is
required for NER (Coin et al., 2007). The XPB ATPase activity is also
required for NER, possibly acting as a wrench to initialize separation of
the DNA helix (Fan et al., 2006). Three diseases are associated with
mutations of XPB or XPD: xeroderma pigmentosum (XP), XP
with Cockayne syndrome (XP/CS), and trichothiodystrophy (TTD)
(Lehmann, 2001). XP patients are prone to skin cancer due to an
inability to complete NER. The XP associated mutation XPB(F99S)
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Fig. 1. Retroviral infection of wild type and NER mutant cell lines. (A) An equal number
of NER mutant (XPB(F99S) and XPD(R683W)) and complemented cells (XPB-wt and
XPD-wt) were infected with HIV or MMLV retroviral vectors expressing GFP following
integration to the host genome. At 72 hpi the cells were analyzed by ﬂow cytometry for
GFP expression. Transduction efﬁciency is expressed relative to the complemented cells
expressing the wild type gene. (B and C) HIV late reverse transcripts in wild type and
NERmutant cells treated with the transcription inhibitor α-amanitin. An equal number
of wild type and NER defective cells were treated with the RNA polymerase II inhibitor
α-amanitin for 2 h and infected with an HIV based retroviral vector in the continued
presence of α-amanitin (a-amanitin). DNA was collected at 6 h after the addition of
HIV. HIV late reverse transcripts (LRT) and the cellular 18S gene were measured by
qPCR. The quantity of HIV LRT was divided by the number of cellular genomes to obtain
the number of HIV LRT per cell (HIV LRT/cell). (B) XPB-wt and NER defective XPB(F99S)
cell lines. (C) XPD-wt and NER defective XPD(R683W) cell lines. Data from α-amanitin
treated cells is expressed relative to untreated cells (No drug). Error bars indicate the
standard deviation between triplicates at two MOI in three independent experiments.
292 K.E. Yoder et al. / Virology 410 (2011) 291–298reduces interaction of XPB with TFIIH subunit p52, which stimulates
XPB ATPase activity at sites of DNA damage (Coin et al., 2007). The XP
associated mutation XPD(R683W) affects interaction of XPD with p44
and helicase activity (Dubaele et al., 2003). Hence it is possible to
identify and isolate cell lines from XP patients with mutations of XPB
or XPD that affect NER. However, deletion of any TFIIH complex gene
is lethal due to its essential role in transcription (Friedberg and Meira,
2006).
Previous studies have shown that XPB and XPD mediated
degradation of retroviral cDNA is associated with NER activity, but
did not directly address the transcription activity of these proteins
during cDNA degradation (Yoder et al., 2006). Here we show that XPB
and XPD mediated cDNA degradation is not due to altered tran-
scription or translation of other host factors. This degradation pathway
is distinct from APOBEC3G or proteasome host defense pathways.
While degradation of cDNA leads to less integratedprovirus in vivo, the
integration efﬁciency in vitro of PICs isolated from XPB or XPD mutant
cells is similar to PICs from wild type cells. Finally, studies of cells
arrested by aphidicolin indicate that TFIIH mediated cDNA degrada-
tion coincides with entry to the nucleus.
Results
XPB and XPD do not affect cDNA accumulation by transcription
Cell lines were derived from XP patients expressing the XPB(F99S)
mutation or the XPD(R683W) mutation (Gozukara et al., 1994; Riou
et al., 1999). These cell lines were complemented with the respective
wild type gene to generate isogenic cell lines XPB-wt and XPD-wt
(Gozukara et al., 1994; Riou et al., 1999). XPB(F99S) and XPD(R683W)
cell lines are more sensitive to UV irradiation compared to the
complemented cell lines, indicating defective NER (Yoder et al., 2006).
Previous studies have shown that retroviral infection, both HIV and
MMLV, is more than 100% greater in XPB(F99S) cell lines compared to
cells expressing the wild type gene; XPD(R683W) cells have 15%
greater retroviral infection efﬁciency compared to cells expressing
wild type XPD (Yoder et al., 2006). The XP cell lineswere infectedwith
HIV or MMLV vector particles expressing GFP following successful
integration. The cells were analyzed for GFP expression by ﬂow
cytometry (Fig. 1A). XPB(F99S) cells showed greater than 100%
increase in HIV or MMLV transduction efﬁciency compared to XPB-wt
cells (HIV P=0.0063, MMLV P=0.022). XPD(R683W) cells also
display an increase in HIV or MMLV transduction efﬁciency (HIV
P=0.0003, MMLV P=0.0005).
The role of XPB and XPD in basal transcription suggests the
possibility that shortly following viral entry to the cell, new host
factors are transcribed that could be responsible for the observed host
defense against retroviral cDNA. To determine whether the TFIIH
proteins are transcribing nascent host factors that mediate cDNA
degradation, XPB-wt and XPB(F99S) cells were treated with the
transcription inhibitor α-amanitin for 2 h (Fig. 1B). In the continued
presence of α-amanitin, cells were infected with an HIV based
retroviral vector encoding GFP (Follenzi et al., 2000). These vector
particles have previously been shown to faithfully recapitulate the
HIV life cycle from reverse transcription through integration (Butler
et al., 2002). DNA was collected at 6 h post infection (hpi), a time
point previously shown to display signiﬁcant differences in cDNA
accumulation betweenmutant andwild type cells (Yoder et al., 2006).
The DNA samples were analyzed for HIV late reverse transcripts (LRT)
by quantitative PCR (qPCR). The LRT qPCR primer set spans the primer
binding site and ampliﬁes all forms of full length HIV cDNA including
linear unintegrated cDNA, 1LTR circles, 2LTR circles, and integrated
provirus (Butler et al., 2001). In both the presence and absence of
α-amanitin, the NER mutant cell line XPB(F99S) showed greater
accumulation of cDNA than XPB-wt cells (Pb0.0001 with or without
α-amanitin, data not shown). If XPB mediates cDNA degradationthrough transcription of new host factors, then treatment with
α-amanitin will prevent the appearance of nascent defense factors
and cDNA accumulation will increase. However, there was no
signiﬁcant difference (XPB-wt P=0.54, XPB(F99S) P=0.19) in
cDNA accumulation between untreated cells and cells treated with
α-amanitin, suggesting that the transcription activity of TFIIH does
not affect retroviral cDNA stability (Fig. 1B). This data is similar to
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efﬁciency between cells expressing XPB-wt and a TTD mutation, XPB
(T119P), which has no effect on NER activity (Coin et al., 2007; Yoder
et al., 2006). XPD-wt and XPD(R683W) cells were also infected in the
presence ofα-amanitin and showed no signiﬁcant difference (XPD-wt
P=0.56, XPD(R683W) P=0.13) in the accumulation of HIV cDNA at 6
hpi (Fig. 1C). These results indicate that TFIIH transcription activity is
not involved in the degradation of retroviral cDNA.
During transcription, the CDK-activating kinase (CAK) subunit of
TFIIH exhibits kinase activity necessary for elongation of a nascent
mRNA transcript (Roy et al., 1994). The drug DRB inhibits the CAK
kinase (Yankulov et al., 1995). DRB was added to the XP cell lines for
2 h prior to the addition of HIV and continued for the ﬁrst 6 hpi to
assess the role of TFIIH kinase activity on cDNA degradation. DRB has
previously been shown to reduce HIV replication by inhibiting Tat
mediated transcription of the integrated HIV provirus (Biglione et al.,
2007; Critchﬁeld et al., 1997). In contrast, this experiment measures
HIV cDNA well before integration of the provirus. Cells were analyzed
for HIV late reverse transcripts by qPCR (Fig. 2A). There was no
signiﬁcant difference in HIV cDNA per cell in any of the XP cell lines
whenDRBwas present (XPB-wt P=0.066, XPB(F99S) P=0.092, XPD-
wt P=0.055, XPD(R683W) P=0.69). Similarly, cells were treated
with DRB and infectedwith anMMLV based retroviral vector (Fig. 2B).
As with HIV, there was no signiﬁcant difference in MMLV LRT per cell
in any cell line when DRB was present (XPB-wt P=0.76, XPB(F99S)
P=0.10, XPD-wt P=0.24, XPD(R683W) P=0.14). The presence of
DRB during the ﬁrst 6 h of retroviral infection appears to have no
signiﬁcant effects on cDNA stability, suggesting that the CAK kinase
activity and TFIIH dependent mRNA transcription elongation do not
participate in cDNA degradation (Fig. 2).
Cycloheximide inhibits the translation of mRNA to protein by the
ribosome. This drug was added to XPB-wt, XPB(F99S), XPD-wt, and0
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Fig. 2.HIV late reverse transcripts in XP cell lines treated with a CAK inhibitor.Wild type
and NERmutant cells were treated with the CAK inhibitor DRB for 2 h and infected with
an HIV based retroviral vector in the continued presence of the drug. DNAwas collected
at 6 h after the addition of HIV. HIV late reverse transcripts (LRT) and the cellular 18S
gene were measured by qPCR and used to determine HIV LRT per cell. (A) XPB-wt and
NER defective XPB(F99S) cell lines. (B) XPD-wt and NER defective XPD(R683W) cell
lines. Data from DRB treated cells is expressed relative to untreated cells (No drug).
Error bars indicate the standard deviation between triplicates at two MOI in three
independent experiments.XPD(R683W) cells for 2 h. The cells were then infectedwith HIV in the
continued presence of cycloheximide. DNA was collected at 6 hpi and
analyzed by qPCR for late reverse transcripts (Fig. 3A). There was no
signiﬁcant difference in HIV cDNA between cells in the presence or
absence of cycloheximide (XPB-wt P=0.14, XPB(F99S) P=0.042,
XPD-wt P=0.49, XPD(R683W) P=0.91). These results suggest that
nascent protein synthesis is not required for cDNA degradation in any
of the XP cell lines. Similarly, cells were infected with MMLV in the
presence of cycloheximide and cDNAwas quantiﬁed at 6 hpi (Fig. 3B).
There was no signiﬁcant difference in MMLV cDNA accumulation
when cycloheximide was present for any of the XP cell lines (XPB-wt
P=0.061, XPB(F99S) P=0.89, XPD-wt P=0.075, XPD(R683W)
P=0.11). Taken as a whole, these results suggest that the transcrip-
tion activity of TFIIH is not involved in the retroviral cDNA degra-
dation pathway.
XPB and XPD mediated cDNA degradation is distinct from other
retroviral cDNA stability pathways
The host protein APOBEC3G deaminates cytosines in retroviral
cDNA during reverse transcription (Harris et al., 2003). Studies have
also suggested that APOBEC3G affects the accumulation of full-length
reverse transcripts, although this observation is controversial
(reviewed in Albin and Harris, 2010). The HIV Vif protein is able to
target human APOBEC3G, but not African green monkey (AGM)
APOBEC3G, to the proteasome for degradation (Mariani et al., 2003).
Thus, HIV particles generated in the presence of AGM APOBEC3G
show signiﬁcantly reduced infectivity compared to virus generated in0
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Fig. 3. HIV late reverse transcripts in wild type and NER mutant XP cell lines treated
with the translation inhibitor cycloheximide. An equal number of (A) XPB-wt and XPB
(F99S) or (B) XPD-wt and XPD(R683W) cells were treated with the ribosome inhibitor
cycloheximide for 2 h and infected with an HIV based retroviral vector in the continued
presence of cycloheximide. DNA was collected at 6 h after the addition of HIV particles.
HIV late reverse transcripts (LRT) and the cellular 18S gene were measured by qPCR.
The quantity of HIV LRT was divided by the number of cellular genomes to obtain the
number of HIV LRT per cell (HIV LRT/cell). Data from cycloheximide treated cells is
expressed relative to untreated cells (No drug). Error bars indicate the standard
deviation between triplicates at two MOI in three independent experiments.
294 K.E. Yoder et al. / Virology 410 (2011) 291–298the presence of human APOBEC3G. HIV based retroviral vector par-
ticles, including the Vif protein, were produced in the presence of
either human APOBEC3G or AGM APOBEC3G. XPB(F99S) and XPB-wt
cells were infected with these vector particles (Fig. 4). Cells were
analyzed by ﬂow cytometry for GFP expression and the percentage of
positive cells is expressed relative to XPB-wt cells. Infection efﬁciency
in the presence of AGM APOBEC3G was consistently 5 fold lower than
human APOBEC3G (data not shown). XPB(F99S) cells displayed
greater infection efﬁciency than XPB-wt cells, conﬁrming previous
reports (Fig. 4A; Yoder et al., 2006). The difference of infection
efﬁciency between XPB(F99S) and XPB-wt cells was similar in the
presence of either human or AGM APOBEC3G (Fig. 4A). In the
presence of AGM APOBEC3G, infection efﬁciency of XPB(F99S) cells
was 98% greater than XPB-wt; in the presence of human APOBEC3G,
the infection efﬁciency of XPB(F99S) was 104% greater than XPB-wt. A
similar pattern was observed for XPD(R683W) andmatchedwild type
cells (Fig. 4B) These results suggest that the difference in infection
efﬁciency between XPB or XPD mutant cells compared to their
matched wild type cells was not affected by the presence of AGM
APOBEC3G or human APOBEC3G. XPB and XPD appear to act on
retroviral cDNA in a pathway that is distinct from APOBEC3G.
Previous studies with proteasome inhibitors led to an increase in
cDNA stability and integration through an unknown mechanism
(Butler et al., 2002; Schwartz et al., 1998). NER defective XPB(F99S)
cells and XPB-wt cells were treated with the highest tolerable doses of0
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Fig. 4. Role of TFIIH in the APOBEC3G host defense pathway. HIV vector particles
including Vif were generated in the presence of African greenmonkey (AGM) or human
APOBEC3G. (A) XPB-wt and XPB(F99S) or (B) XPD-wt and XPD(R683W) cells were
infected with AGM or human APOBEC3G HIV vectors. The HIV vector expresses GFP
following integration. Cells were assayed by ﬂow cytometry for GFP expression from
the integrated HIV cDNA. The infection efﬁciency of mutant cell lines is expressed
relative to wild type cells and % difference graphed. Error bars indicate the standard
deviation between duplicates at two MOI in two independent experiments.proteasome inhibitors MG132, lactacystin, and clasto-lactacystin β-
lactone or a different protease inhibitor, calpain inhibitor I (Fig. 5A). In
the continued presence of drug, cells were infected with HIV
expressing GFP following integration. The cells were evaluated by
ﬂow cytometry for GFP expression at 72 hpi; data is shown relative to
infection efﬁciency in the absence of drug. The addition of proteasome
inhibitors slightly increased HIV infection efﬁciency but only
signiﬁcantly in the presence of clasto-lactacystin β-lactone (no drug
vs. clasto-lactacystin β-lactone: XPB-wt P=0.0016, XPB(F99S)
P=0.01; Fig. 5A). There was no signiﬁcant difference between
matched XPB NER mutant and wild type cells (Fig. 5A, MG132
P=0.11, lactacystin P=0.20, clasto-lactacystin β-lactone P=0.15).
An inhibitor that does not target the proteasome, calpain inhibitor I,
also did not display a signiﬁcant difference between XPB mutant and
wild type cells (calpain inhibitor I P=0.14). Similar results were
observed with the NER mutant XPD(R683W) and XPD-wt cell lines
(Fig. 5B, MG132 P=0.40, lactacystin P=0.075, clasto-lactacystin
β-lactone P=0.63). This data suggests that the proteasome effects on
cDNA accumulation appear to be unrelated to XPB/XPD mediated
cDNA degradation.
XPB and XPD do not affect PIC-mediated integration in vitro
Our previous studies showed that integration efﬁciency increases
in the presence of NERmutant XPB or XPD (Yoder et al., 2006). Change
of integration efﬁciency could be due to direct effects of XPB/XPD
proteins on the enzymatic activity of the integration complex or wild0
0.5
1
1.5
No drug Mg132 Lactacystin cLL LLnL
H
IV
 tr
an
sd
uc
tio
n 
ef
fic
ie
nc
y
XPD-wt XPD(R683W)
0
0.5
1
1.5
2
2.5
No drug MG132 Lactacystin cLL LLnL
H
IV
 tr
an
sd
uc
tio
n 
ef
fic
ie
nc
y
XPB-wt XPB(F99S)A
B
Fig. 5. Effects of proteasome inhibitors on HIV infection efﬁciency in XP cell lines.
(A) XPB-wt and XPB(F99S) cells were infected with HIV vector particles in the presence
of 2 μM MG132, 2 μM lactacystin, 2 μM clasto-lactacystin β-lactone (cLL), or 5 μM
calpain inhibitor I (LLnL). (B) XPD-wt and XPD(R683W) cells were infected with HIV
vector particles in the presence of 0.5 μM MG132, 2.5 μM lactacystin, 1 μM clasto-
lactacystin β-lactone (cLL), or 50 μM calpain inhibitor I (LLnL). The HIV vector particles
express GFP following integration and cells were assayed by ﬂow cytometry for GFP
expression at 72 hpi. Infection efﬁciency is expressed relative to cells infected in the
presence of DMSO (No drug). Error bars indicate the standard deviation between
duplicates at two MOI in three independent experiments.
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Fig. 6. Integration efﬁciency of PICs derived fromXP cell lines. XPB-wt (complemented),
XPB(F99S), XPD-wt (complemented), and XPD(R683W) cell lines were infected with
HIV vector particles. PIC extracts were harvested at 6 hpi. 100 ng human genomic DNA
was added to PICs as an integration target and incubated at 37 °C for 1 h. DNA was
puriﬁed and assayed by qPCR for late reverse transcripts and integration products. The
PIC integration efﬁciency is expressed relative to PICs from wild type complemented
cells. Error bars indicate the standard deviation between duplicate integration reactions
from two independent preparations of PICs.
295K.E. Yoder et al. / Virology 410 (2011) 291–298type XPB/XPD may simply reduce the number of full length cDNAs
available for integration. The effects of XPB and XPD on integrase
catalytic activity were evaluated with pre-integration complexes
(PICs, Fig. 6). PICs were isolated from infected cells 6 h after HIV
particles were added to the cells. An exogenous target DNAwas added
to the PICs allowing integration in vitro (Farnet and Haseltine, 1990).
The integration efﬁciency of PICs was calculated as the number of
integrated proviruses divided by the total number of complete late
reverse transcripts measured by qPCR. PICs were prepared from XPB
(F99S), XPB-wt, XPD(R683W), and XPD-wt cells (Fig. 6). Genomic
DNA from uninfected 293T cells was added to the PICs as an
exogenous DNA target. Integration efﬁciency was measured by qPCR
and is expressed relative to PICs from wild type cells. We found no
signiﬁcant differences in the integration efﬁciency between PICs
prepared from matched NER mutant and wild type cells (Fig. 6, XPB
P=0.053, XPD P=0.14). These results suggest that XPB and XPD are
unlikely to directly affect the integration reaction.
Degradation of retroviral cDNA coincides with entry to the nucleus
XPB and XPD proteins appear to have no effect on integration
efﬁciency in vitro, yet they alter the frequency of integration events in
vivo (Fig. 6; Yoder et al., 2006). As a nuclear resident, it is likely that
TFIIH does not interact with retroviral cDNA until the PIC enters the
nucleus (Coin et al., 2006). However, differences in HIV cDNA
accumulation have been observed at time points before entry to the
nucleus in cycling cells (Yoder et al., 2006). To determine the
subcellular localization of TFIIH mediated cDNA degradation, XPB
cells were arrested at G1/S by treating with aphidicolin for 18 h and
infecting with an HIV vector in the continued presence of aphidicolin.Fig. 7. Infection of XPB cell lines in the presence of aphidicolin. XPB-wt (open
diamonds) and XPB(F99S) (ﬁlled squares) cells were treated with 1 μg/ml aphidicolin
for 18 h before infection and arrested at G1/S. HIV vector particles were added in the
continued presence of aphidicolin. DNA was collected at 6, 24, 30, 48, and 72 h post
infection and analyzed by qPCR for the accumulation of (A) HIV late reverse transcripts
(LRT), (B) HIV 2LTR circles. The 18S gene was quantiﬁed to yield the number of HIV
cDNAs per cell. (C and D) XPB-wt (open diamonds) and XPB(F99S) (ﬁlled squares) cells
were treated with 1 μg/ml aphidicolin for 18 h before infection and arrested at G1/S.
MMLV vector particles were added in the continued presence of aphidicolin.
Aphidicolin was removed at 24 hpi. DNA was collected at 8, 24, 27, 30, and 48 h post
infection and analyzed by qPCR for the accumulation of (C) MMLV late reverse
transcripts (LRT) and (D) MMLV 2LTR circles. The 18S gene was quantiﬁed to yield the
number of MMLV LRT per cell. Error bars indicate the standard deviation between
duplicates in two independent experiments.
296 K.E. Yoder et al. / Virology 410 (2011) 291–298Aphidicolin is an inhibitor of cellular DNA replication polymerases
and induces accumulation of cells in G1/S phases of the cell cycle
(Supplemental Fig. 1). The numbers of late reverse transcripts (LRT)
and 2LTR circles per cell at 6, 21, 30, 48, and 72 hpi were determined
by qPCR (Figs. 7A and B, respectively). 2LTR circles serve as an
indicator of nuclear entry since this form of cDNA is only found in the
nucleus (Bukrinsky et al., 1992). The appearance of 2LTR circles
indicates that although the cells are arrested, HIV PICs are able to
enter the nucleus (Fig. 7B).
At 6 hpi there are no detectable HIV 2LTR circles, indicating that
the HIV cDNA is still in the cytoplasm while TFIIH proteins are
sequestered in the nucleus. At this early time point the amount of LRT
is similar for both XPB NER mutant and XPB-wt cells (Fig. 7A). This
suggests that cDNA synthesis by reverse transcriptase in the
cytoplasm of arrested cells is not affected by nuclear XPB. 2LTR circles
begin to appear at 21 hpi indicating that the HIV cDNA has begun to
enter the nucleus (Fig. 7B). At this time point differences in the
number of cDNA molecules in mutant and wild type cells begin to
appear. Cells expressing wild type XPB have fewer cDNA molecules at
21 hpi compared to XPB(F99S). XPB-wt cells have 37% LRT compared
to XPB(F99S) cells at 21 hpi (Fig. 7A). This observation suggests that
although a similar number of cDNA molecules are synthesized and
enter the nucleus, the wild type XPB cells display a more robust cDNA
degradation activity.
Unlike HIV, MMLV is not able to enter the nucleus of arrested cells.
XPB(F99S) and XPB-wt cells were treated with aphidicolin for 18 h to
induce a G1/S arrest (Supplemental Fig. 1). These cells were infected
with MMLV in the continued presence of aphidicolin for 24 h (Figs. 7C
and D). At 24 hpi, aphidicolin was removed; this allows the cell cycle
to resume, the nuclear envelope to breakdown, and MMLV cDNA to
enter the nucleus. DNA was puriﬁed at 8, 24, 27, 30, and 48 hpi and
analyzed by qPCR for MMLV LRTs and 2LTR circles (Figs. 7C and D,
respectively). 2LTR circles are an indicator of MMLV cDNA entry to the
nucleus and are only observed at time points after aphidicolin is
removed (Fig. 7D). At 8 hpi and 24 hpi when aphidicolin is present,
the accumulation of MMLV LRTs appears similar in XPB-wt and XPB
(F99S) cells (8 hpi P=0.76, 24 hpi P=0.80). When aphidicolin is
removed from the culture, XPB-wt cells showed an immediate decline
in MMLV cDNA. In contrast, the XPB(F99S) cells do not degrade the
MMLV cDNA to the same extent as the XPB-wt cells (Fig. 7C, 27 hpi
P=0.0004, 30 hpi P=0.01, 48 hpi P=0.0002). The degradation of
MMLV cDNA only occurs when the aphidicolin mediated cell cycle
arrest is removed and is less in the presence of a DNA repair mutant
XPB. When compared with the HIV infection studies (Figs. 7A and B),
these results are consistent with the conclusion that XPB mediated
cDNA degradation coincides with entry to the nucleus.
Discussion
The fates of retroviral cDNA include degradation, 1LTR or 2LTR
circle formation, and integration. Only the integrated provirus is able
to continue the viral life cycle (Cofﬁn et al., 1997). A signiﬁcant
fraction of complete reverse transcripts will not become an integrated
provirus (Barbosa et al., 1994; Brussel and Sonigo, 2003; Butler et al.,
2002; Van Maele et al., 2003; Vandegraaff et al., 2001). The dead-end
fates of circularization and degradation appear to effectively defend
the host genome from invading DNA molecules. Retroviral 2LTR
circles are only found in the nucleus and may be formed by host DNA
repair factors (Bukrinsky et al., 1992; Li et al., 2001). This study
suggests that at least a fraction of retroviral cDNA degradation events
also occur in the nucleus and involve host DNA repair proteins.
A previous study of XPB and XPD showed differences in the
accumulation of cDNA at early time points before nuclear entry in
cycling cells (Yoder et al., 2006). To more accurately determine the
subcellular localization of TFIIH mediated cDNA degradation, we
arrested XPB cell lines with aphidicolin. At the earliest time point inthe presence of aphidicolin, the number of HIV late reverse transcripts
was the same in both NER mutant and wild type cells. Detection of
2LTR circles indicated when HIV cDNA entered the nucleus. The
appearance of 2LTR circles correlated with a signiﬁcant difference in
cDNA accumulation between wild type and mutant cells. Infection of
arrested cells with MMLV also showed that cDNA accumulation was
similar in XPB-wt and XPB(F99S) cells. Only when aphidicolin was
removed and cells could resume cycling did the MMLV cDNA begin to
degrade in both cell lines. The degradation ofMMLV cDNAwas greater
in XPB-wt cells compared to XPB(F99S) cells. These results strongly
suggest that cDNA degradation occurs in the nucleus and that wild
type TFIIH protein XPB participates in the degradation of retroviral
cDNA.
The TFIIH complex is required for basal transcription and NER
(Lehmann, 2001). Each of these processes involves a distinct subset of
cellular partners. Additional factors that participate in TFIIH mediated
degradation of retroviral cDNA remain to be identiﬁed. Other host
defense pathways, including APOBEC3G and proteasome associated
pathways, are apparently not related to the XPB/XPD cDNA degrada-
tion pathway. Additionally, TFIIH transcription activity does not
appear to be involved in retroviral defense either directly or indirectly
by transcribing additional genes. While NER associated mutants of
XPB and XPD reduce cDNA degradation, previous studies indicated
that other NER factors, including XPA and XPC, do not participate in
cDNA degradation (Yoder et al., 2006; data not shown). Additional
proteins that participate in the TFIIH mediated cDNA degradation
pathway, including an exonuclease or endonuclease, may not be part
of transcription or NER pathways and remain to be identiﬁed.
The mechanism of TFIIH cDNA degradation is also mysterious. The
substrate preference of XPD has been exhaustively evaluated in vitro
(Rudolf et al., 2010). The XPD helicase will unwind a substrate with a
5′ overhang or a 5′ ﬂap of DNA, but not a 3′ overhang or a 3′ ﬂap. The
ends of retroviral cDNA are 5′ dinucleotide overhangs after processing
by integrase (Cofﬁn et al., 1997). Lentiviruses also display a 5′ ﬂap of
DNA at the central polypurine tract (cPPT). This feature is likely not
required for TFIIH mediated cDNA degradation since MMLV does not
have a cPPT. Additional studies should identify the features of the
retroviral cDNA that are required for cDNA degradation.
There are few identiﬁed individuals world-wide with mutations of
XPB, 9 patients, or XPD, less than 60 patients (Lehmann, 2001; Oh
et al., 2006). It is statistically unlikely that individuals with mutations
of XPB or XPD will acquire a retroviral infection. However, there are
two XPD single nucleotide polymorphisms, XPD(D312N) and XPD
(K751Q), that change the coding sequence of the protein and occur at
N1% frequency in the general population (Clarkson and Wood, 2005).
Many studies have evaluated the role of XPD polymorphisms in the
development of cancer; careful review suggests that an association of
lung cancer and XPD(D312N) and XPD(K751Q) is unclear (Benhamou
and Sarasin, 2005). However, a recent study of XPD(K751Q) and HIV
infection concluded that this polymorphism may associate with
accelerated disease progression (Sobti et al., 2010). Further study will
be required to assess any role of TFIIH polymorphisms on HIV
infection and disease progression.
Materials and methods
Cell lines
All media reagents were obtained from Invitrogen. XPB cell lines
include the XP/CS patient derived cell line XPCS2BASV expressing the
mutant allele XPB(F99S) (referred to in the text as XPB(F99S)) and the
XPCS2BASV cell line complemented with the wild type XPB allele
(XPCS2BASV+LXPBSNA, referred to in the text as XPB-wt) (Riou
et al., 1999). The second XPB allele in the XPB(F99S) cell line is a
truncation mutant that is not expressed (Oh et al., 2006). XPB(F99S)
derived cell lines were transformed with SV40 large T antigen (Riou
297K.E. Yoder et al. / Virology 410 (2011) 291–298et al., 1999). XPB(F99S) and XPB-wt cell lines were grown in DMEM/
F12 media supplemented with 10% heat inactivated fetal bovine
serum, penicillin, streptomycin, and L-glutamine.
XPD cell lines include the XP patient derived cell line XP6BE(SV40)
encoding two XPD mutations, one allele encodes a 78 nucleotide
deletion which is not expressed and the second allele encodes the
expressed XPD(R683W) mutation (referred to in the text as XPD
(R683W)) (Gozukara et al., 1994). This XPD(R683W) mutant cell line
was complementedwith thewild type XPD allele and called here XPD-
wt (XP6BE-ER2-9; Gozukara et al., 1994). The XPD(R683W) derived
cell lines were grown in DMEM supplemented with 10% heat
inactivated fetal bovine serum, penicillin, streptomycin, and L-glutamine.
The XPD-wt cell line was also supplemented with 600 μg/ml G418.
Drugs
Cells were treated with varying amounts of α-amanitin (Sigma),
cycloheximide (Sigma), or 5,6-dichloro-1-b-D-ribofuranosylbenzimida-
zole (DRB, Calbiochem) for 24 h to determine the highest tolerated dose
for each cell line (data not shown). The cytotoxicity was similar for all
the cell lines and cells were treated with 25 μg/ml α-amanitin, 100 μg/
ml cycloheximide, or 10 μMDRB. TheXPcell lineswere also treatedwith
varying concentrations of proteasome inhibitors to determine the
highest tolerable dose for each cell line (data not shown). XPB-wt and
XPB(F99S) cells were treated with 2 μM lactacystin, 2 μMMG132, 2 μM
clasto-lactacystin β-lactone, and 5 μM calpain inhibitor I (Calbiochem).
XPD-wt and XPD(R683W) cells were treated with 2.5 μM lactacystin,
0.5 μM MG132, 1 μM clasto-lactacystin β-lactone, and 50 μM calpain
inhibitor I. Cellswere treatedwith varying concentrations of aphidicolin
(Sigma) to determine theminimal dosage required to arrest cells at G1/
S. XPB(F99S) and XPB-wt cells were treated with 1 μg/ml aphidicolin.
Infections
HIV based retroviral vector particleswere produced by transfecting
293T cells with three plasmids: an envelope plasmid coding the VSV-G
protein (Stratagene), a packaging construct derived from HIV pΔR8.2
(Zufferey et al., 1997), and a genomic RNA construct also derived from
HIV but coding only for GFP (Follenzi et al., 2000). A fourth plasmid
encoding either human APOBEC3G or African green monkey APO-
BEC3G was included in the transfection for some experiments (a kind
gift fromN. Landau, NYU;Mariani et al., 2003). MMLV based retroviral
vector particles were produced similarly to HIV but using an MMLV
derived packaging construct (HIT60) and genomic RNA construct
pLEGFP-C1 (Clontech; Cannon et al., 1996). The MMLV genomic
construct also coded only a GFP gene. Following transfection, super-
natants were collected, ﬁltered to remove producer cells, and treated
with DNaseI (Roche; Lu et al., 2004).
For infections, cells were plated at equal densities into 6 well
dishes. Cell lines were infected with the HIV or MMLV based retroviral
vector particles at two multiplicities of infection (MOI) in the
presence of 10 μg/ml DEAE dextran (Sigma) in triplicate. The media
was replaced after 2 h in the continued presence of drug where
indicated. For ﬂow cytometry analysis of infection efﬁciency, after
72 h the cells were trypsinized, washed with PBS, ﬁxed with 4%
paraformaldehyde (Sigma), and analyzed for GFP expression by ﬂow
cytometry (BD FACS Calibur and Cellquest software).
Quantitative PCR
Cellswere trypsinized andwashedwith PBS at indicated time points
following infection. Total DNAwas puriﬁed byDNeasy Blood and Tissue
Kit (Qiagen). HIV DNA formswere quantiﬁedwith previously described
primer sets to late reverse transcripts, and 2LTR circles (Butler et al.,
2001; Chiu et al., 2005). The MMLV LRT primer set spans the MMLV
primer binding site and includes primers KY366 5′ AGCTTACCTCCC-GGTGGTGG 3′, KY372 5′ TCTCCTCTGAGTGATTGACTACC 3′, and probe
KY364 5′ FAM-CATTTGGGGGCTCGTCCGGGAT-TAMRA 3′. The MMLV
2LTR circle primer set is primersKY3675′GCGTTACTTAAGCTAGCTTGCC
3′ and KY368 5′ GCGTCGCCCGGGTACCCG 3′ and probe KY369 5′ FAM-
GGTAGTCAATCACTCAGAGGAG-TAMRA 3′. The number of cellular
genomes present per sample was quantiﬁed by primers to the 18S
gene (Applied Biosystems). Absolute quantitation was performed with
known amounts of plasmid standards or cellular genomeswith Taqman
mastermix in an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) at the Ohio State University Comprehensive
Cancer Center Nucleic Acid Shared Resource. The amount of retroviral
DNAwasdividedby thenumberof cellular genomes toyield the amount
of retroviral DNA per cell. All qPCR reactions were performed in
triplicate.
Integration reactions in vitro
Cells were infected with HIV based retroviral vector particles as
described (Hansen et al., 1999). After 6 h, the cells were trypsinized
and washed with Buffer K (20 mM HEPES, pH 7.4, 150 mM KCl, and
5 mM MgCl2). Cells were resuspended in Buffer K with 1 mM DTT,
0.5% NP-40, and protease inhibitors and incubated on ice for 10 min.
The PIC extracts were spun at 3000×g for 3 min and then 10,000×g for
3 min. The supernatant was frozen with liquid nitrogen and stored at
−80 °C. 100 ng genomic DNA from uninfected 293T cells was added
to the PICs and incubated at 37 °C for 1 h. DNA was then isolated from
the integration reactions by the DNeasy Blood and Tissue Kit (Qiagen).
Late reverse transcripts and integrated provirus were measured by
qPCR as described (Brussel and Sonigo, 2003; Butler et al., 2001; Lu
et al., 2005; Vandegraaff et al., 2006). A negative control of HIV PICs
with no target (0% integration) and a positive control of genomic DNA
from infected cells passaged for multiple generations (100% integra-
tion) were included. The total amount of late reverse transcripts was
measured by qPCR indicating the total number of unintegrated and
integrated PICs present in each sample. 104 late reverse transcripts
were ampliﬁed with 100 nM each of the previously described primers
L-M667, Alu1, and Alu2, for 20 cycles (Brussel and Sonigo, 2003). The
reaction products were diluted 1:10 and ampliﬁed by qPCR with
300 nM primers Lambda T and AA55M and 200 nM probe MH603
(Brussel and Sonigo, 2003; Butler et al., 2001). The integration
efﬁciency of HIV PICs derived from mutant cells is expressed relative
to integration of HIV PICs derived from wild type cells.
Statistical analysis
Data in Figs. 1B, C, 2, 3, and 5 is expressed relative to no drug
present. Data in Figs. 1A, 4, and 6 is expressed relative to wild type
cells. Flow cytometry and qPCR data was analyzed by paired t test to
generate two-tailed P values (GraphPad Prism 4, San Diego). P values
were rounded to two signiﬁcant ﬁgures.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.11.016.
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